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Abstract
Despite gastric cancer being rare nowadays in Western countries, it remains one of the leading causes of cancer death
worldwide. The course of the disease varies, so the individual gastric cancer patient’s prognosis is difficult to determine.
The need for new biomarkers is crucial. The aim of this study was to evaluate the prognostic value of serum matrix
metalloproteinase-8, serum tissue inhibitor of metalloproteinase-1, and tissue matrix metalloproteinase-8 in patients
with gastric cancer. Preoperative serum samples from 233 patients with gastric cancer were retrospectively analyzed.
Serum levels of matrix metalloproteinase-8 were analyzed with immunofluorometric assay, and tissue inhibitor of metal-
loproteinase-1 levels were determined by enzyme-linked immunosorbent assay. We also determined the tissue expres-
sion of matrix metalloproteinase-8 in 276 gastric cancer samples by immunohistochemistry. Survival data and death
causes came from patient records, the Population Register Center of Finland, and Statistics Finland. Patients with a low
(\31 ng/mL) or high (.131 ng/mL) serum matrix metalloproteinase-8 level had a considerably unfavorable prognosis
(p = 0.002). Those patients with a high (170 ng/mL) serum tissue inhibitor of metalloproteinase-1 level also had a poor
prognosis (p \ 0.001), and the latter remained significant in multivariable analysis (hazard ratio = 1.85; 95% confidence
interval: 1.26–2.72; p = 0.002). The molar ratio of serum matrix metalloproteinase-8 and tissue inhibitor of metallopro-
teinase-1 levels with low (\0.07) or high (.0.30) molar ratios predicted a worse prognosis (p = 0.020). Tissue matrix
metalloproteinase-8 did not influence prognosis. These results suggest that serum matrix metalloproteinase-8, tissue
inhibitor of metalloproteinase-1, and the ratio of matrix metalloproteinase-8/ tissue inhibitor of metalloproteinase-1 may
prove useful biomarkers for prediction of prognosis in patients with gastric cancer.
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Introduction
Gastric cancer is the world’s fifth most common cancer
type, with almost one million new cases annually; it is
the third leading cause of cancer-related death with
annually approximately 723,000 deaths. The 5-year sur-
vival rate, even after curative surgery, is only about
30%.1–3 Estimation of gastric cancer prognosis relies
on the tumor node metastasis (TNM) classification;
additional prognostic information may come from
biomarkers.
1Department of Surgery, University of Helsinki and Helsinki University
Hospital, Helsinki, Finland
2Research Programs Unit, Translational Cancer Biology, University of
Helsinki, Helsinki, Finland
3Department of Pathology, University of Helsinki and HUSLAB, Helsinki
University Hospital, Helsinki, Finland
4Department of Oral and Maxillofacial Diseases, Helsinki University
Hospital and Biomedicum Helsinki, Helsinki, Finland
5Department of Dental Medicine, Karolinska Institutet, Huddinge,
Sweden
Corresponding author:
Alli Laitinen, Department of Surgery, University of Helsinki and Helsinki
University Hospital, Haartmaninkatu 4, P.O. Box 440 Helsinki, FIN-00029
HUS Finland.
Email: alli.laitinen@helsinki.fi
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial
use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and
Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
The matrix metalloproteinases (MMPs), proteinases
participating in extracellular matrix (ECM) degrada-
tion, are structurally related but genetically differing
zinc-dependent endoproteases that hydrolyze compo-
nents of the ECM.4 They play an important role in
many steps of cancer development, regulating the
microenvironment of the tumor by regulating cancer
cell growth, differentiation, apoptosis, and immune sur-
veillance. Increased expression and activation of certain
MMPs occurs in many human cancers, and overexpres-
sion is often associated with poor prognosis.5
Although MMPs have traditionally been associated
with cancer progression because of their ability to
degrade the ECM, some MMPs have recently been
identified as having anti-tumor properties and tumor-
resistant functions. MMP-8, also known as collage-
nase-2, is produced mainly by neutrophils and has been
involved in a variety of inflammatory conditions.
MMP-8’s protective role in cancer may operate through
its ability to regulate the inflammatory response.6,7
Tissue inhibitor of metalloproteinase-1 (TIMP-1) is
one of the naturally presenting inhibitors of MMPs.
Although it is vital in inhibiting MMPs, it works inde-
pendently in tumor invasion and metastasis. Several
studies have shown that high TIMP-1 levels are associ-
ated with aggressive tumors and worse prognosis in
malignancies, including gastric cancer.8,9 ECM degra-
dation is an essential step of cancer invasion and metas-
tasis.10 Basement-membrane proteolysis depends on a
balance between activities of MMPs and their
inhibitors.11
Gastric cancer is a highly malignant disease with an
unfortunate prognosis. Clinical practice would benefit
from having prognostic biomarkers to evaluate tumor
behavior and tumor response to treatment. Here, we
studied serum levels of MMP-8 and TIMP-1 and also
the immunoexpression of MMP-8 in gastric cancer tis-
sues in relation to clinicopathological parameters.
Methods
Patients
The study cohort comprised 313 gastric cancer patients
who underwent surgery for histologically verified gas-
tric adenocarcinoma at the Department of Surgery,
Helsinki University Hospital, between 2000 and 2009.
The surgical method was total gastrectomy for 153
(48.9%) cases and partial gastrectomy for 160 (51.1%).
Of the 313, 228 (72.8%) were operated on with curative
intent, whereas 85 (27.2%) underwent palliative sur-
gery. Their median age was 67.4 (interquartile range
(IQR): 57.1–76.6) and 161 (51.4%) were women.
According to the 7th edition of the UICC classification,
stage distribution was 62 (19.9%) stage IA-IB, 72
(23.1%) stage IIA-IIB, 115 (36.8%) stage IIIA-IIIC,
and 63 (20.2%) stage IV patients. Lymph-node metas-
tases appeared in 198 (65.6%) and distant metastases
in 63 (20.1%). Of these 313 gastric cancer patients, 15
(4.8%) received preoperative treatment, and 125
(39.9%) postoperative adjuvant treatment (74 che-
motherapy, 2 radiotherapy, and 50 both). Survival data
and death causes until September 2017 came from
patient records, the Population Register Center of
Finland, and Statistics Finland.
The Surgical Ethics Committee of Helsinki
University Hospital (Dnro HUS 226/E6/ 06, extension
TMK02 §66 17.4.2013) and the National Supervisory
Authority of Welfare and Health (Valvira Dnro 10041/
06.01.03.01/2012) gave their permission to use the tis-
sue samples without individual consent in this retro-
spective study.
Serum samples
The 233 blood samples from gastric cancer patients
were collected within 24 days prior to surgery (range 0–
24days). Most of the samples (95.7%) were taken
within 3 days prior to the gastric cancer operation. The
samples were centrifuged, and serum and plasma com-
ponents stored as aliquots at 280C until analysis.
Serum levels of MMP-8 were determined by time-
resolved immunofluorometric assay (IFMA) (Medix
Biochemica, Espoo, Finland) according to manufactur-
er’s instructions; the detection limit for MMP-8 was
0.08 ng/mL.12 Serum levels of TIMP-1 were detectable
with the commercially available enzyme-linked immu-
nosorbent assay (ELISA) kit according to manufactur-
er’s instructions (Biotrak ELISA System; Amersham
Biosciences, Buckinghamshire, UK) and the detection
limit chosen was 1.25 ng/mL.13 For calculation of
MMP-8/TIMP-1 molar ratios, concentration units
(ng/mL) were converted to molarity units (mol/l) by
use of the molecular weights of MMP-8 and TIMP-1,
respectively.4
Tissue samples and immunohistochemistry
Tissue samples from 283 patients were available; these
formalin-fixed and paraffin-embedded surgical-tissue
samples came from the archives of the Department of
Pathology, University of Helsinki. Once de-identified,
they were analyzed anonymously. An experienced
pathologist re-evaluated all histological slides and then
defined and marked areas representing the highest
grade of each individual tumor. In total, four 1.0mm
cores from each tumor block: two from the invasive
front and two from the tumor center were sampled and
embedded in a new paraffin block with a semi-
automatic tissue microarrayer (Tissue Arrayer 1,
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Beecher Instruments Inc., Silver Spring, MD, USA) as
described.14 For immunohistochemistry, sections of
4mm were cut and processed.
Sections were fixed on slides and dried for 12–24
hours at 37C then were deparaffinized in xylene and
rehydrated through step-by-step decreasing concentra-
tions of ethanol to distilled water. For antigen retrieval,
sections were treated in a PreTreatment module (Lab
Vision Corp., Fremont, CA, USA) in Tris-HCl (pH
8.5) and in Tris-ethylenediaminetetraacetic acid
(EDTA) (pH 9) buffer for 20minutes at 98C. Sections
were stained in an Autostainer 480 (Lab Vision Corp.,
Fremont, CA, USA). Tissues were incubated with a
specific polyclonal rabbit anti-human antibody15,16
diluted to 1:400 overnight at room temperature.
Tissues from the colon and breast served for positive
staining control.
Scoring of immunoreactivity
MMP-8 immunoreactivity was successfully scored in
276 tumors, scoring based on cytoplasmic MMP-8
intensity in cancer cells as 0–3. Strong positive immu-
noreactivity was scored as 3, moderate positivity 2, weak
positivity 1, and negative immunoreactivity as 0. Tissue
samples were scored independently by two researchers
(A.L. and J.H.) without knowledge of patients’ clinical
status or outcome data. Samples with conflicting scores
were re-evaluated until consensus. Of the four cores, the
one with the highest score served for further analysis.
Statistical analysis
To determine the significance of difference in biomar-
ker median serum concentrations among gastric cancer
Table 1. Significance of the difference in MMP-8 and TIMP-1 serum concentrations and MMP-8/TIMP-1 molar ratio in 233 gastric
cancer patients.
Clinicopathological variable MMP-8 (ng/mL) TIMP-1 (ng/mL) MMP-8/TIMP-1 (molar ratio)
Median (IQR) p-value Median (IQR) p-value Median (IQR) p-value
Agea
\67 57.8 (31.5–106) 0.561 145 (128–166) \0.001 0.18 (0.09–0.30) 0.034
67 50.8 (27.6–104) 175 (148–203) 0.13 (0.07–0.23)
Gendera
Male 52.4 (30.8–107) 0.997 156 (134–185) 0.973 0.15 (0.08–0.29) 0.943
Female 57.4 (30.6–100) 159 (132–188) 0.16 (0.09–0.26)
TNM stageb
IA-IB 50.4 (32.0–104) 0.929 156 (134–177) 0.201 0.17 (0.08–0.29) 0.978
IIA-IIB 52.0 (30.8–94.4) 155 (133–190) 0.14 (0.09–0.24)
IIIA-IIIC 53.2 (27.6–112) 152 (132–177) 0.17 (0.08–0.31)
IV 57.8 (29.4–127) 174 (135–201) 0.16 (0.08–0.22)
Tumor classification (pT)b
pT1 49.2 (32.0–127) 0.773 156 (132–189) 0.588 0.14 (0.07–0.29) 0.946
pT2 52.0 (33.6–84.4) 155 (136–175) 0.14 (0.09–0.25)
pT3 56.8 (26.4–106) 152 (133–180) 0.13 (0.08–0.29)
pT4 57.6 (36.2–117) 163 (131–200) 0.17 (0.08–0.27)
Lymph node metastasis (pN)a
pN0 55.0 (32.0–103) 0.689 151 (129–182) 0.383 0.17 (0.09–0.29) 0.489
pN1-3 52.2 (27.6–107) 156 (134–186) 0.15 (0.08–0.27)
Distant metastasis (pM)a
pM0 52.4 (30.8–104) 0.573 154 (132–180) 0.035 0.15 (0.08–0.29) 0.963
pM1 57.8 (29.4–127) 174 (135–201) 0.16 (0.08–0.22)
Laurén classificationa
Intestinal 67.0 (36.0–116) 0.044 166 (144–192) 0.021 0.18 (0.10–0.30) 0.132
Diffuse 49.2 (26.4–95.2) 149 (129–180) 0.15 (0.07–0.26)
Tumor size, cma
<6.0 53.6 (31.7–104) 0.999 151 (132–180) 0.250 0.16 (0.09–0.29) 0.774
.6.0 57.0 (26.7–112) 160 (136–191) 0.16 (0.08–0.27)
MMP-8 immunohistochemistrya
Negative 50.0 (27.6–104) 0.186 150 (129–177) 0.008 0.16 (0.08–0.27) 0.501
Positive 65.0 (36.2–106) 169 (143–190) 0.16 (0.09–0.28)
MMP-8: matrix metalloproteinase-8; TIMP-1: tissue inhibitor of matrix metalloproteinase-1; IQR: interquartile range.
aMann-Whitney U-test.
bKruskal-Wallis test.
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subgroups, the Mann–Whitney U-test and Kruskal–
Wallis test were applied. Survival curves were con-
structed according to the Kaplan-Meier method and
compared with the Log Rank test. Cancer-specific sur-
vival was calculated from date of surgery to date of
death from gastric cancer or until September 2017. For
serum biomarkers MMP-8 and TIMP-1, and the
MMP-8/TIMP-1 molar ratio we determined optimal
cut-offs by the aid of receiver-operating characteristic
(ROC) curves and found them to identify suitable
groups for survival analyses. For multivariable survival
analysis, the Cox proportional hazard model had the
following covariates entered: age, gender, stage, TNM
classification, Lauréns classification, tumor size, serum
level of MMP-8 and TIMP-1, the MMP-8/TIMP-1
molar ratio, and MMP-8 immunohistochemical expres-
sion. A p-value of \0.05 was considered statistically
significant. All statistical analyses were performed with
IBM SPSS Statistics version 22.0–25.0 (IBM
Corporation, Armonk, NY, USA).
Results
Of the 233 serum samples, median MMP-8 level prior
to gastric cancer surgery was 54.8 ng/mL (IQR: 30.8–
105ng/mL) and 156ng/mL (IQR: 132–187 ng/mL) for
TIMP-1. Median molar ratio of MMP-8 and TIMP-1
was 0.153 (IQR: 0.082–0.280). Serum levels of MMP-8
were higher in patients with intestinal cancer
(p=0.044, Mann–Whitney U-test). TIMP-1 serum lev-
els were higher among patients over 67 years (p
\ 0.001), ones with metastasized disease (p=0.035),
with intestinal cancer (p=0.021), and in samples with
positive MMP-8 immunohistochemistry (p=0.008). In
addition, the MMP-8/TIMP-1 molar ratio was higher
among patients under 67 (p=0.034, Table 1).
Serum MMP-8 and TIMP-1 univariable survival
analyses
When we investigated optimal cut-offs by the aid of
ROC curves, we found them to provide suitable groups
for survival analyses. For MMP-8, we used cut-offs of
31 ng/mL and 131ng/mL, finding that patients both
with low and with high serum MMP-8 levels had con-
siderably worse prognosis than did patients with an
intermediate MMP-8 level (p=0.002, Log Rank test,
Figure 1(a)). Patients with high serum TIMP-1 (cut-off
170 ng/mL) had worse prognosis (p\ 0.001, Log Rank
test, Figure 1(b)). We also investigated the molar ratio
of serum MMP-8 and TIMP-1 levels and found by
ROC curve analysis two cut-offs (0.07 and 0.30).
Patients with a low or high molar ratio had worse prog-
nosis than did those with an intermediate ratio
(p=0.020, Log Rank test, Figure 1(c)).
Serum MMP-8 and TIMP-1 subgroup analyses
In subgroup analyses, survival was favorable in patients
with an intermediate MMP-8 serum level (31 to 131ng/
mL) in TNM stages I-II (p=0.003, Figure 2(a)). In




Figure 1. Cancer-specific survival in gastric cancer patients
according to the Kaplan-Meir method. Serum levels of (a) MMP-
8, (b) TIMP-1, and (c) MMP-8/TIMP-1 molar ratio. p-value for
Log Rank test.
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levels (\ 170ng/mL) had a better prognosis (p\ 0.001,
Figure 2(b)). An intermediate MMP-8 level (31–131 ng/
mL) and a low TIMP-1 level (\ 170ng/mL) were sig-
nificant markers of better prognosis in both the
intestinal type and the diffuse cancer type (Figures
2(c)–2(f)). Other subgroups studied together with the
cumulative 5-year survival according to the Kaplan–
Meier method are in Tables 2 and 3.
Figure 2. Cancer-specific survival of subgroups of gastric cancer patients according to the Kaplan-Meier method. Serum levels of
(a) MMP-8 in patients with stage I-II disease, (b) TIMP-1 in patients with stage III-IV disease. Serum MMP-8 in patients with (c)
intestinal, (d) diffuse type cancer. Serum TIMP-1 in patients with (e) intestinal, and (f) diffuse type cancer. p-value for Log Rank test.
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Serum MMP-8 and TIMP-1 multivariable survival
analyses
In multivariable survival analysis, we found that age,
TNM stage, Laurén classification, and high TIMP-1
level (170ng/mL) served as independent prognostic
factors (Table 4).
MMP-8 expression in tumor tissues
MMP-8 immunoreactivity was possible to score in 276
(97.5%) tissue microarray samples. Cytoplasmic immu-
nostaining was negative in 157 (56.9%), weak in 85
(30.8%), moderate in 30 (10.9%), and strong in 4
(1.4%) cases. For the final analysis, we dichotomized
the scores into negative (score 0) and positive (scores
1–3) immunostaining. For representative images of
immunostainings, see Figure 3.
Association of MMP-8 tissue expression with
clinicopathological variables
Negative MMP-8 immunostaining was associated with
patient age under 67 (p=0.007), with stage I cancer
(p=0.022), with tumor classification T1 (p=0.005),
with cancer without lymph node metastasis (p=0.016),
and with diffuse cancer type (p\ 0.001, Table 5).
Tissue MMP-8 univariable survival analyses and
subgroup analyses
No significant difference emerged in gastric-cancer-
specific survival (p=0.178). The 5-year survival rate
for negative immunostaining was 46.3% (95% confi-
dence interval (CI) 38.1–54.5) and for positive, 36.3%
(95% CI 27.1–45.5, data not shown). In subgroup anal-
yses, prognosis was better for those with negative
Table 2. Kaplan-Meier analysis for serum disease-specific survival stratified for serum MMP-8 concentrations in subgroups of gastric
cancer patients. p-value for log-rank test.




\67 35.9 (18.1–53.7) 53.9 (42.3–65.5) 48.1 (26.7–69.5) 0.100
67 21.8 (4.36–39.2) 52.0 (38.3–65.7) 23.5 (3.31–43.7) 0.015
Gender
Men 39.4 (19.4–59.4) 56.2 (43.5–68.9) 28.3 (7.33–49.3) 0.004
Women 22.2 (6.91–37.5) 50.2 (38.1–62.4) 45.0 (23.2–66.8) 0.087
TNM stage
I-II 55.3 (33.4–77.3) 89.4 (81.4–97.4) 66.7 (40.0–93.4) 0.003
III-IV 14.0 (1.65–26.4) 20.1 (10.1–30.1) 23.1 (6.83–39.4) 0.719
Tumor classification (T)
T1 87.5 (64.6–100) 94.4 (83.8–100) 83.3 (53.5–100) 0.655
T2 55.6 (6.99–100) 91.6 (80.4–100) 33.3 (0–86.6) \0.001
T3 12.7 (0–26.2) 39.5 (23.4–55.6) 41.7 (13.9–69.5) 0.011
T4 17.0 (0–36.6) 21.2 (8.66–33.7) 23.5 (3.31–43.7) 0.696
Lymph node metastasis (N)
N0 60.9 (36.4–85.4) 85.6 (75.0–96.2) 66.7 (35.9–97.5) 0.109
N + 17.0 (4.01–29.9) 38.6 (27.4–49.8) 30.8 (13.0–48.6) 0.037
Distant metastasis (M)
M0 28.5 (14.8–42.2) 63.0 (53.6–72.4) 50.2 (31.8–68.6) \0.001
M1 34.3 (31.4–65.5) 6.30 (0–17.9) 10.0 (0–28.6) 0.005
Laurén classification
Intestinal 55.6 (28.9–82.3) 65.8 (51.7–79.9) 37.5 (13.8–61.2) 0.022
Diffuse 20.5 (7.56–33.4) 45.7 (34.7–56.7) 36.8 (16.6–57.0) 0.038
Tumor size
<6 cm 48.5 (30.3–66.7) 73.0 (62.8–83.2) 43.5 (22.3–64.7) 0.001
.6 cm 6.10 (0–17.5) 23.1 (11.0–35.3) 29.4 (7.64–51.2) 0.735
MMP-8 immunohistochemistry
Negative 35.3 (19.0–51.6) 56.4 (43.5–69.3) 33.7 (13.5–53.9) 0.040
Positive 8.30 (0–23.8) 47.0 (33.7–60.3) 30.8 (5.71–55.9) 0.010
MMP-8: matrix metalloproteinase-8, CI: confidence interval.
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Table 3. Kaplan-Meier analysis for serum disease-specific survival stratified for serum TIMP-1 concentrations in subgroups of gastric
cancer patients. P-value for log-rank test.




\67 54.0 (44.0–64.0) 28.9 (11.1–46.7) 0.012
67 48.6 (33.5–63.7) 31.6 (18.9–44.3) 0.038
Gender
Men 54.3 (42.5–66.1) 32.5 (15.6–49.4) 0.024
Women 50.6 (38.8–62.4) 29.3 (16.0–42.6) 0.003
TNM stage
I-II 79.6 (69.6–89.6) 76.9 (60.6–93.2) 0.705
III-IV 28.7 (18.3–39.1) 4.90 (0–11.4) \0.001
Tumor classification (pT)
pT1 95.0 (85.4–100) 81.8 (59.1–100) 0.190
pT2 83.6 (68.9–98.3) 63.5 (30.4–96.6) 0.124
pT3 32.1 (19.6–44.6) 29.6 (8.63–50.6) 0.665
pT4 34.3 (19.2–49.4) 6.70 (0–15.3) \0.001
Lymph node metastasis (pN)
pN0 76.3 (64.0–88.7) 79.7 (61.9–97.5) 0.809
pN + 41.5 (31.1–51.9) 14.0 (4.00–24.0) \0.001
Distant metastasis (pM)
pM0 57.5 (48.7–66.3) 41.1 (28.0–54.2) 0.018
pM1 16.8 (0–34.1) 9.10 (0–21.1) 0.016
Laurén classification
Intestinal 70.5 (57.0–84.0) 39.5 (21.5–57.5) 0.002
Diffuse 43.7 (33.7–53.7) 25.0 (12.5–37.5) 0.005
Tumor size
<6 cm 68.2 (58.2–78.2) 49.3 (33.6–65.0) 0.024
.6 cm 28.0 (15.5–40.5) 10.9 (0.12–21.7) 0.002
MMP-8 immunohistochemistry
Negative 50.0 (39.2–60.8) 35.4 (18.2–52.7) 0.164
Positive 51.6 (36.3–66.9) 24.1 (10.6–37.6) \0.001
TIMP-1: tissue inhibitor of matrix metalloproteinase-1, CI: confidence interval.
Table 4. Multivariable Cox regression analysis of cancer-specific survival for gastric cancer patients.
Hazard ratio 95% CI p-value
Age, years
\67 1.00
67 1.95 1.32–2.87 0.001
TNM stage
IA-IB 1.00
IIA-IIB 7.06 2.41–20.7 \0.001
IIIA-IIIC 22.7 8.20–62.7 \0.001
IV 75.7 26.1–220 \0.001
Laurén classification
Intestinal 1.00
Diffuse 2.27 1.52–3.37 \0.001
TIMP-1 level, ng/mL
\170 1.00
170 1.85 1.26–2.72 0.002
TIMP-1: tissue inhibitor of metalloproteinases-1; CI: confidence interval.
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MMP-8 immunostaining among women (p=0.026)
and among those with low (\31ng/mL) serum MMP-
8 (p=0.018, data not shown). When MMP-8 immu-
nostainings were analyzed as two subgroups, negative
and positive, we found that intermediate (31–131 ng/
mL) serum MMP-8 level was a significant marker of
better prognosis in both subgroups (p=0.040,
p=0.010; Supplementary figure A-B). In addition, low
Figure 3. Representative images of MMP-8 immunostaining in gastric cancer tumors with (a) negative and (b) positive staining.
Original magnification x40.
Table 5. Association of MMP-8 immunohistochemistry with clinicopathological variables in 276 gastric cancer patients.
Clinicopathological variable n MMP-8 immunostaining p-value
Negative Positive
n % n %
Age
\67 137 89 65.0 48 35.0 0.007
 67 139 68 48.9 71 51.1
Gender
Male 134 78 58.2 56 41.8 0.666
Female 142 79 55.6 63 44.4
TNM stage
IA-IB 49 37 75.5 12 24.5 0.022
IIA-IIB 64 36 56.3 28 43.8
IIIA-IIIC 104 51 49.0 53 51.0
IV 58 32 55.2 26 44.8
Tumor classification (pT)
pT1 37 31 83.8 6 16.2 0.005
pT2 41 23 56.1 18 43.9
pT3 87 45 51.7 42 48.3
pT4 111 58 52.3 53 47.7
Lymph node metastasis (pN)
pN0 87 58 66.7 29 33.3 0.016
pN1-3 180 92 51.1 88 48.9
Distant metastasis (pM)
pM0 218 125 57.3 93 42.7 0.767
pM1 58 32 55.2 26 44.8
Laurén classification
Intestinal 111 48 43.2 63 56.8 \0.001
Diffuse 165 109 66.1 56 33.9
Tumor size, cm
<6.0 149 91 61.1 58 38.9 0.069
.6.0 120 60 50.0 60 50.0
MMP-8: matrix metalloproteinase-8.
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(\170 ng/mL) TIMP-1 level was a significant marker
of better prognosis only in the subgroup of MMP-8-
positive immunostaining (p\ 0.001), not in MMP-8-
negative (p=0.164, Supplementary figure C-D).
Discussion
Here, we show, to our knowledge for the first time, that
gastric cancer patients with either low or high preo-
perative serum MMP-8 value had a considerably worse
prognosis, and we also strengthen the findings that
patients with elevated serum TIMP-1 levels have a poor
outcome.
Interestingly, a worse prognosis was evident both in
patients with low MMP-8 level and in those with a high
level compared with those with an intermediate MMP-
8 level. This phenomenon has not yet been described in
a clinical patient series. MMP-8 takes part in many bio-
logical processes and is shown to also have antitumor
properties. MMP-8 deficient mice have shown to
develop skin tumors and tongue cancer more often
than wild type mice.6,7 In addition, in breast cancer
cells, MMP-8 expression causes a decrease in tumor
growth and lung metastasis formation proving an evi-
dence of MMP-8 antitumor function in cancer and
metastasis.17 Korpi et al. showed also that in a clinical
patient cohort of tongue cancer, MMP-8 expression is
significantly linked with prolonged survival.7 In con-
trast, high MMP-8 levels have also been associated
with advanced cancer type and poor patient outcome
in hepatocellular and colorectal cancer.18,19
Our serum MMP-8 findings differ from those of
most markers that have only one cut-off dividing the
patients into those with poor or with good prognosis.
Our results indicate that a normal physiological level of
MMP-8 is the most favorable for the patient and that
either lack of MMP-8 or excess MMP-8 favors cancer
aggressiveness. The role of MMP-8 seems to be more
complex than that of other MMPs in various tissues.
In multivariable analysis, high serum TIMP-1 level
served as an independent marker of worse prognosis.
TIMP-1 plays an independent role in maintaining the
balance between ECM deposition and degradation in
healthy and malignant tissues. In cancer, TIMP-1 can
exert an effect on tumor growth, invasion, and metasta-
sis.20 Thus, our finding strengthens the earlier findings
in gastric cancer.8,9 Earlier, only one gastric cancer
study before ours showed that patients with elevated
TIMP-1 levels had poor prognosis when using disease-
specific survival as an endpoint as we did.21 Thus, our
study strengthens knowledge concerning TIMP-1 as a
biomarker of poor prognosis in gastric cancer.
As we measured, the serum levels of both MMP-8
and TIMP-1, knowing how these two interact in tissues
when TIMP-1 binds MMPs in a 1:1 stoichiometry, it
was interesting to calculate also the molar ratio of these
two markers. After the nonlinear MMP-8 result, it was
reasonable also to find two cut-offs for their molar
ratio, and patients with low or high molar ratio had
worse prognosis than those with intermediate ratio.
Interestingly, tissue MMP-8 did not influence prog-
nosis. This finding indicates that the same biomarker’s
serum level and tissue expression do not necessarily cor-
relate. Differences occur in how it is expressed in tumor
tissue and the amounts of the active protein in circula-
tion. In gastric cancer, the active serum MMP-8, we
measured may originate in different sources related to
cancer rather than originating in the tumor tissue itself.
In addition, serum or plasma levels of MMP-8 are
also elevated in certain cardiovascular diseases, in
Helicobacter pylori infection, and in periodontitis.12,22–26
The strength of this study is a large gastric cancer
patient population with both serum and tissue microar-
ray samples, and with reliable and lengthy clinical
follow-up data. The tissue microarray method allows
analysis of only small spots from each tumor, but on
the other hand, the whole tumor cohort can be stained
as one batch without risk of variation between staining
series; moreover, this method makes it possible to eval-
uate a large number of patient samples in a moderate
length of time.
In conclusion, both serum MMP-8 and its inhibitor
TIMP-1 are promising prognostic markers for gastric
cancer. MMP-8 tissue expression had no prognostic
value. Our results are promising but need to be vali-
dated in other patient cohorts.
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